Abstract: Percutaneous coronary intervention (PCI) is the main non-surgical method for releasing severe coronary stenosis. Postoperative dual antiplatelet drug therapy can effectively prevent the emergence of various thrombotic complications and reduce the occurrence of cardiovascular events and mortality. However, in recent years, there has been much controversy over the best maintenance dose of aspirin and clopidogrel after PCI. The article reviews large numbers of studies and guidelines both at home and abroad and discusses the application prospect of new antiplatelet agents.